目的:研究CRM197对裸鼠卵巢癌移植瘤生长的抑制作用探讨其对逆转卵巢癌组织耐药作用及其在卵巢癌治疗中的可行性.方法:用人卵巢癌亲本细胞A2780、耐紫杉醇细胞A2780/Taxol及耐顺铂细胞A2780/DDP分别建立裸鼠卵巢癌移植瘤模型,观察注射CRM197组与阴性对照组裸鼠肿瘤生长情况,免疫组化法测定各组裸鼠肿瘤组织中HB-EGF及P-gp表达情况.结果:HB-EGF及P-gp在各肿瘤组织中不同程度的表达,在注射CRM197的裸鼠肿瘤组织中表达明显降低(P＜0.05),差异具有统计学意义.结论:CRM197通过抑制肝素结合表皮生长因子的信号传导通路激活抑制了裸鼠卵巢癌移植瘤的生长,使裸鼠卵巢癌移植瘤HB-EGF及P-gp表达明显降低.%Objective: To investigate the reversal effect of CRM197 on drug-resistant ovarian cancer and its treatment for ovarian cancer by researching the inhibition of CRM197 for the xenografts of ovarian cancer in nude mice. Methods: The parental ovarian cancer cell A2780, cells resistant to paclitaxel A2780/Taxol and cisplatin-resistant cells A2780/DDP were used to establish the xenograft model in nude mice, the differentiation for the growth of xenograft tumors in the group which was injected with CRM197 and the negative control group was detected. Immunohistochemistry was used to test the expression of HB-EGF and P-gp in xenograft tumors of each team. Results: The expression of HB-EGF and P-gp were in different levels in each group. It was depressed obviously in the xenograft tumors which were injected CRM197. The difference was significant in statistics. Conclusion: The inhibition of CRM197 on the activation of the signal transduction pathway of heparin-binding epidermal growth factor inhibited the growth of the xenograft tumors of ovarian cancer and depressed the expression of HB-EGF and P-gp in xenograft tumors.
展开▼
